Precigen, Inc. (NASDAQ:PGEN) SVP Buys $49,999.55 in Stock

Precigen, Inc. (NASDAQ:PGEN) SVP Jeffrey Thomas Perez bought 58,823 shares of the stock in a transaction that occurred on Friday, August 9th. The shares were purchased at an average cost of $0.85 per share, for a total transaction of $49,999.55. Following the completion of the acquisition, the senior vice president now owns 743,097 shares of the company’s stock, valued at $631,632.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Precigen Trading Down 4.5 %

NASDAQ PGEN opened at $1.07 on Friday. The firm’s 50 day moving average price is $1.52 and its two-hundred day moving average price is $1.46. Precigen, Inc. has a twelve month low of $0.84 and a twelve month high of $1.93.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Precigen had a negative net margin of 3,084.55% and a negative return on equity of 76.35%. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.54 million. During the same period in the previous year, the firm posted ($0.10) earnings per share. Sell-side analysts forecast that Precigen, Inc. will post -0.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PGEN. Stifel Nicolaus lifted their price objective on shares of Precigen from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, June 3rd. HC Wainwright decreased their price target on shares of Precigen from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Precigen in a research report on Wednesday, May 15th. StockNews.com raised Precigen to a “sell” rating in a research note on Thursday, August 1st. Finally, JMP Securities cut their target price on Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a research report on Thursday. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $7.00.

Hedge Funds Weigh In On Precigen

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC boosted its holdings in shares of Precigen by 12.5% during the fourth quarter. SG Americas Securities LLC now owns 76,352 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 8,478 shares during the period. ClariVest Asset Management LLC boosted its stake in shares of Precigen by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 492,152 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 13,752 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Precigen by 40.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 16,486 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Precigen by 56.7% in the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 18,097 shares during the last quarter. Finally, Fortis Group Advisors LLC purchased a new stake in shares of Precigen during the first quarter worth $28,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.